on 03 Jan 2023
Last Applicant/ Owned by
CH-3930 Visp
CH
Serial Number
79339202 filed on 01st Feb 2022
Registration Number
6938347 registered on 03rd Jan 2023
Correspondent Address
Lawrence J. Crain
Filing Basis
No Filing Basis
Disclaimer
NO DATA
Legal services in the field of patent exploitation, namely, patent licensing; licensing of intellectual property in the field of monoclonal and trimeric antibodies for laboratories, diagnostics and analytics for scientific or research use Pharmaceutical preparations based on human monoclonal or trimeric antibodies and derivatives thereof for treating cancers, inflammatory diseases, autoimmune disRead More
Legal services in the field of patent exploitation, namely, patent licensing; licensing of intellectual property in the field of monoclonal and trimeric antibodies for laboratories, diagnostics and analytics for scientific or research use
Downloadable computer software for scientific laboratory research and commercial use for applications with monoclonal or trimeric antibodies used to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, namely, software for an algorithm to generate antibody sequences
Pharmaceutical preparations based on human monoclonal or trimeric antibodies and derivatives thereof for treating cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases, for use in related diagnostic or therapeutic use, and for use as medical diagnostic assays for testing of body fluids or tissues, for use in disease detection, including, cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases
Biochemicals, namely, monoclonal and trimeric antibodies and derivatives thereof for in-vivo or in-vitro scientific research and development to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases and for use in laboratories, diagnostics and analytics for scientific or research use
Medical and scientific research in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; medical research services, namely, protein engineering in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; pharmaceutical product development in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; industrial research in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; and contract research services in the fields of human monoclonal or trimeric antibodies to treat cancers, inflammatory diseases, autoimmune diseases, infectious diseases and cardiovascular diseases; computer programming for acquisition and processing of medical data in the context of medical-scientific research, development and therapy with monoclonal or trimeric antibodies and their derivatives
No 79339202
No Service Mark
No 6665.149943
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 20th Apr 2023 | FINAL DISPOSITION PROCESSED |
| 20th Apr 2023 | FINAL DISPOSITION NOTICE SENT TO IB |
| 03rd Apr 2023 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| 03rd Jan 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 03rd Jan 2023 | REGISTERED-PRINCIPAL REGISTER |
| 18th Oct 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 18th Oct 2022 | PUBLISHED FOR OPPOSITION |
| 28th Sep 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 21st Sep 2022 | REFUSAL PROCESSED BY IB |
| 13th Sep 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
